Xinji Shaxi (03603) issued a profit warning, expecting that the net loss attributable to shareholders for the year 2025 will be approximately 22 million to 32 million yuan, representing a narrowing compared to the previous year.
Sinogomei Creek (03603) announced that for the fiscal year ending December 31, 2024 (2024 fiscal year), the attributable net loss to shareholders was approximately RMB 162 million. It is expected that for the fiscal year ending December 31, 2025 (2025 fiscal year), the attributable net loss to shareholders for this group will be no less than RMB 22 million but not more than RMB 32 million.
XINJI SHAXI (03603) announces that compared to the net loss attributable to shareholders of approximately RMB 162 million for the fiscal year ending on December 31, 2024 (2024 fiscal year), it is expected that the net loss attributable to shareholders of this group for the fiscal year ending on December 31, 2025 (2025 fiscal year) will be no less than RMB 22 million but no more than RMB 32 million.
The Board of Directors believes that the expected decrease in the net loss attributable to shareholders for the 2025 fiscal year is mainly due to the decrease in fair value loss of investment properties held by this group, as (i) the renovation plan of "XINJI SHAXI Hotel Supplies Expo City" has been delayed, leading to improvement in its operating conditions, and (ii) the decrease in rental rates of two malls in Shenyang is expected to narrow compared to the previous year, resulting in a reduction in the estimated valuation loss for the 2025 fiscal year compared to the 2024 fiscal year.
Despite the above circumstances, excluding the impact of certain one-off or non-recurring items, including changes in fair value of investment properties and related income tax expenses on these adjustment items (which the Board of Directors does not consider as indicators used to evaluate the actual performance of this group), the core net profit of this group for the 2025 fiscal year is expected to decrease by no more than RMB 200 million compared to the core net profit for the 2024 fiscal year, which was approximately RMB 73.8 million.
Related Articles

HENLIUS (02696) announced its annual performance, with revenue of 6.67 billion RMB, representing a year-on-year growth of 16.46%.

Shengtak New Materials (300881.SZ) has received approval from the Shenzhen Stock Exchange for the issuance of convertible bonds.

HENLIUS (02696)Naluriyou monoclonal anti-drug similar to drug HLX18 (recombinant humanized monoclonal antibody injection) for the treatment of various solid tumors has received approval from the National Medical Products Administration for phase 1 clinical trial application.
HENLIUS (02696) announced its annual performance, with revenue of 6.67 billion RMB, representing a year-on-year growth of 16.46%.

Shengtak New Materials (300881.SZ) has received approval from the Shenzhen Stock Exchange for the issuance of convertible bonds.

HENLIUS (02696)Naluriyou monoclonal anti-drug similar to drug HLX18 (recombinant humanized monoclonal antibody injection) for the treatment of various solid tumors has received approval from the National Medical Products Administration for phase 1 clinical trial application.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


